Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C20H30O2 |
Molecular Weight | 302.451 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 7 / 7 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC[C@](C)(O)[C@@]1(C)CC[C@]3([H])[C@@]4([H])CCC(=O)C=C4C[C@@H](C)[C@@]23[H]
InChI
InChIKey=PTQMMNYJKCSPET-OMHQDGTGSA-N
InChI=1S/C20H30O2/c1-12-10-13-11-14(21)4-5-15(13)16-6-8-19(2)17(18(12)16)7-9-20(19,3)22/h11-12,15-18,22H,4-10H2,1-3H3/t12-,15+,16-,17+,18-,19+,20+/m1/s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/2422638Curator's Comment: Description was created based on several sources, including
http://www.skylocke.com/pdf_txt/CHEQUE-Drops.PDF | https://www.ncbi.nlm.nih.gov/pubmed/18515094 | https://anabolic.org/cheque-drops-mibolerone/
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2422638
Curator's Comment: Description was created based on several sources, including
http://www.skylocke.com/pdf_txt/CHEQUE-Drops.PDF | https://www.ncbi.nlm.nih.gov/pubmed/18515094 | https://anabolic.org/cheque-drops-mibolerone/
Mibolerone is a synthetic anabolic steroid. It binds both androgen and progesterone receptors and exerts both androgenic and progestagenic actions.
Mibolerone (CHEQUE® Drops) was used in veterinary for estrous (heat) prevention in adult female dogs not intended primarily for breeding purposes. No prescription preparation, human or veterinary, is currently known to contain mibolerone worldwide.
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Activation of androgen receptor in epidermal growth factor modulation of fetal mouse sexual differentiation. | 1996 Oct 14 |
|
Expression of the human androgen receptor in eukaryotic cells using a recombinant adenovirus vector yields high levels of the soluble, functional receptor protein. | 2001 Dec |
|
Characterization of intracellular aggregates using fluorescently-tagged polyglutamine-expanded androgen receptor. | 2001 Jul |
|
Regulation of u-PA gene expression in human prostate cancer. | 2001 Nov 1 |
|
Melatonin elicits nuclear exclusion of the human androgen receptor and attenuates its activity. | 2001 Oct 1 |
|
Role of androgens in female genital sexual arousal: receptor expression, structure, and function. | 2002 Apr |
|
The F-box protein SKP2 mediates androgen control of p27 stability in LNCaP human prostate cancer cells. | 2002 Aug 20 |
|
Effect of geldanamycin on androgen receptor function and stability. | 2002 Jan |
|
The human ovarian surface epithelium is an androgen responsive tissue. | 2002 Mar 18 |
|
Effects of a diphenyl ether-type herbicide, chlornitrofen, and its amino derivative on androgen and estrogen receptor activities. | 2003 Apr |
|
Suppression of prostate tumor growth by U19, a novel testosterone-regulated apoptosis inducer. | 2003 Aug 1 |
|
The use of androgen receptor amino/carboxyl-terminal interaction assays to investigate androgen receptor gene mutations in subjects with varying degrees of androgen insensitivity. | 2003 May |
|
Androgens inhibit estradiol-17beta synthesis in Atlantic croaker (Micropogonias undulatus) ovaries by a nongenomic mechanism initiated at the cell surface. | 2003 Nov |
|
Probasin promoter (ARR(2)PB)-driven, prostate-specific expression of the human sodium iodide symporter (h-NIS) for targeted radioiodine therapy of prostate cancer. | 2003 Nov 15 |
|
Study of 202 natural, synthetic, and environmental chemicals for binding to the androgen receptor. | 2003 Oct |
|
Forced expression of heat-shock protein 70 increases the secretion of Hsp70 and provides protection against tumour growth. | 2004 Feb 23 |
|
Dexamethasone enhances the cytotoxic effect of radioiodine therapy in prostate cancer cells expressing the sodium iodide symporter. | 2004 Mar |
|
Estimation of estrogenic and antiestrogenic activities of selected pesticides by MCF-7 cell proliferation assay. | 2004 May |
|
Methyl selenium metabolites decrease prostate-specific antigen expression by inducing protein degradation and suppressing androgen-stimulated transcription. | 2004 May |
|
Studies of targeting and intracellular trafficking of an anti-androgen doxorubicin-formaldehyde conjugate in PC-3 prostate cancer cells bearing androgen receptor-GFP chimera. | 2004 Nov 4 |
|
Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence. | 2004 Oct 1 |
|
Involvement of transcription factor Sp1 in quercetin-mediated inhibitory effect on the androgen receptor in human prostate cancer cells. | 2005 Apr |
|
Stem/progenitor and intermediate cell types and the origin of human prostate cancer. | 2005 Dec |
|
[Regulation of expression of pituitary tumor transforming gene 1 (PTTG1) by androgen in prostate cancer]. | 2005 Dec 18 |
|
The Estradiol-Dihydrotestosterone model of prostate cancer. | 2005 Mar 18 |
|
Androgen-induced mineralization by MC3T3-E1 osteoblastic cells reveals a critical window of hormone responsiveness. | 2005 Mar 18 |
|
Acquisition of androgen independence by human prostate epithelial cells during arsenic-induced malignant transformation. | 2005 Sep |
|
COMPRENDO: Focus and approach. | 2006 Apr |
|
Collision-induced dissociation pathways of anabolic steroids by electrospray ionization tandem mass spectrometry. | 2006 Apr |
|
Contraception in felids. | 2006 Jul 1 |
|
Perillyl alcohol inhibits the expression and function of the androgen receptor in human prostate cancer cells. | 2006 May 18 |
|
Expression and function of the human androgen-responsive gene ADI1 in prostate cancer. | 2007 Aug |
|
Estrogen signaling and disruption of androgen metabolism in acquired androgen-independence during cadmium carcinogenesis in human prostate epithelial cells. | 2007 Feb 1 |
|
Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs. | 2007 Jul 17 |
|
Steroids with a carbamate function at C-17, a novel class of inhibitors for human and hamster steroid 5alpha-reductase. | 2007 Oct |
|
Oriental herbs as a source of novel anti-androgen and prostate cancer chemopreventive agents. | 2007 Sep |
|
Androgen receptor functional analyses by high throughput imaging: determination of ligand, cell cycle, and mutation-specific effects. | 2008 |
|
Antiproliferative actions of the synthetic androgen, mibolerone, in breast cancer cells are mediated by both androgen and progesterone receptors. | 2008 Jun |
|
Steroid and beta-adrenergic receptor modifications in target organs of broiler chickens fed with a diet containing beta2-adrenergic agents. | 2008 Jun |
|
In vivo and in vitro effect of novel 4,16-pregnadiene-6,20-dione derivatives, as 5alpha-reductase inhibitors. | 2008 Sep |
|
Synthesis and biological effect of halogen substituted phenyl acetic acid derivatives of progesterone as potent progesterone receptor antagonists. | 2008 Sep |
|
Biological activity of novel progesterone derivatives having a bulky ester side chains at C-3. | 2008 Sep |
|
Manipulating prohibitin levels provides evidence for an in vivo role in androgen regulation of prostate tumours. | 2009 Dec |
|
Androgen receptor mutations associated with androgen insensitivity syndrome: a high content analysis approach leading to personalized medicine. | 2009 Dec 9 |
|
Aromatic esters of progesterone as 5alpha-reductase and prostate growth inhibitors. | 2009 Jun |
|
Novel C-6 substituted and unsubstituted pregnane derivatives as 5alpha-reductase inhibitors and their effect on hamster flank organs diameter size. | 2009 Oct |
|
Regulation of growth hormone receptors in human prostate cancer cell lines. | 2009 Oct 15 |
|
A novel anticancer agent, retigeric acid B, displays proliferation inhibition, S phase arrest and apoptosis activation in human prostate cancer cells. | 2010 Dec 5 |
|
Androgens modulate autophagy and cell death via regulation of the endoplasmic reticulum chaperone glucose-regulated protein 78/BiP in prostate cancer cells. | 2010 Sep 9 |
|
Effects of treatment with androgen receptor ligands on microRNA expression of prostate cancer cells. | 2015 Jul 3 |
Sample Use Guides
In Vivo Use Guide
Sources: http://www.skylocke.com/pdf_txt/CHEQUE-Drops.PDF
CHEQUE® DROPS mibolerone 100 ug/ml
female dogs: 1 to 25 lbs - 30 ug, 26 to 50 lbs - 60 ug, 51 to 100 lbs - 120 ug, 101 and over lbs - 180 ug orally once each day by adding to a small amount of food or directly to the mouth
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18515094
Whereas high physiological doses (10-100nM) of 5alpha-dihydrotestosterone reduced E(2)-mediated induction of the estrogen-regulated gene progesterone receptor (PR) to basal levels, mibolerone at lower doses (1nM) eliminated PR expression, suggesting that mibolerone may also act via the PR.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C243
Created by
admin on Sat Dec 16 16:03:20 GMT 2023 , Edited by admin on Sat Dec 16 16:03:20 GMT 2023
|
||
|
CFR |
21 CFR 520.1430
Created by
admin on Sat Dec 16 16:03:20 GMT 2023 , Edited by admin on Sat Dec 16 16:03:20 GMT 2023
|
||
|
WIKIPEDIA |
Designer-drugs-Mibolerone
Created by
admin on Sat Dec 16 16:03:20 GMT 2023 , Edited by admin on Sat Dec 16 16:03:20 GMT 2023
|
||
|
DEA NO. |
4000
Created by
admin on Sat Dec 16 16:03:20 GMT 2023 , Edited by admin on Sat Dec 16 16:03:20 GMT 2023
|
||
|
CFR |
21 CFR 558.348
Created by
admin on Sat Dec 16 16:03:20 GMT 2023 , Edited by admin on Sat Dec 16 16:03:20 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB08941MIG
Created by
admin on Sat Dec 16 16:03:20 GMT 2023 , Edited by admin on Sat Dec 16 16:03:20 GMT 2023
|
PRIMARY | |||
|
3203
Created by
admin on Sat Dec 16 16:03:20 GMT 2023 , Edited by admin on Sat Dec 16 16:03:20 GMT 2023
|
PRIMARY | |||
|
251636
Created by
admin on Sat Dec 16 16:03:20 GMT 2023 , Edited by admin on Sat Dec 16 16:03:20 GMT 2023
|
PRIMARY | |||
|
DB11429
Created by
admin on Sat Dec 16 16:03:20 GMT 2023 , Edited by admin on Sat Dec 16 16:03:20 GMT 2023
|
PRIMARY | |||
|
C100075
Created by
admin on Sat Dec 16 16:03:20 GMT 2023 , Edited by admin on Sat Dec 16 16:03:20 GMT 2023
|
PRIMARY | |||
|
CHEMBL425863
Created by
admin on Sat Dec 16 16:03:20 GMT 2023 , Edited by admin on Sat Dec 16 16:03:20 GMT 2023
|
PRIMARY | |||
|
100000081184
Created by
admin on Sat Dec 16 16:03:20 GMT 2023 , Edited by admin on Sat Dec 16 16:03:20 GMT 2023
|
PRIMARY | |||
|
72260
Created by
admin on Sat Dec 16 16:03:20 GMT 2023 , Edited by admin on Sat Dec 16 16:03:20 GMT 2023
|
PRIMARY | |||
|
3704-09-4
Created by
admin on Sat Dec 16 16:03:20 GMT 2023 , Edited by admin on Sat Dec 16 16:03:20 GMT 2023
|
PRIMARY | |||
|
34849
Created by
admin on Sat Dec 16 16:03:20 GMT 2023 , Edited by admin on Sat Dec 16 16:03:20 GMT 2023
|
PRIMARY | |||
|
DTXSID4036489
Created by
admin on Sat Dec 16 16:03:20 GMT 2023 , Edited by admin on Sat Dec 16 16:03:20 GMT 2023
|
PRIMARY | |||
|
1443362
Created by
admin on Sat Dec 16 16:03:20 GMT 2023 , Edited by admin on Sat Dec 16 16:03:20 GMT 2023
|
PRIMARY | |||
|
C72100
Created by
admin on Sat Dec 16 16:03:20 GMT 2023 , Edited by admin on Sat Dec 16 16:03:20 GMT 2023
|
PRIMARY | |||
|
223-046-5
Created by
admin on Sat Dec 16 16:03:20 GMT 2023 , Edited by admin on Sat Dec 16 16:03:20 GMT 2023
|
PRIMARY | |||
|
9OGY4BOR8D
Created by
admin on Sat Dec 16 16:03:20 GMT 2023 , Edited by admin on Sat Dec 16 16:03:20 GMT 2023
|
PRIMARY | |||
|
MIBOLERONE
Created by
admin on Sat Dec 16 16:03:20 GMT 2023 , Edited by admin on Sat Dec 16 16:03:20 GMT 2023
|
PRIMARY | |||
|
m7523
Created by
admin on Sat Dec 16 16:03:20 GMT 2023 , Edited by admin on Sat Dec 16 16:03:20 GMT 2023
|
PRIMARY | Merck Index |
ACTIVE MOIETY